Profusa, Inc. (NASDAQ:PFSA) Sees Large Growth in Short Interest

Profusa, Inc. (NASDAQ:PFSA) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totaling 160,653 shares, an increase of 409.3% from the September 15th total of 31,545 shares. Based on an average trading volume of 9,017,408 shares, the short-interest ratio is presently 0.0 days. Currently, 31.2% of the shares of the company are short sold.

Profusa Trading Down 8.5%

PFSA traded down $0.12 on Monday, hitting $1.30. 264,412 shares of the company’s stock traded hands, compared to its average volume of 928,584. The company’s 50 day simple moving average is $3.66 and its 200-day simple moving average is $25.82. The firm has a market cap of $787,800.00, a price-to-earnings ratio of -0.00 and a beta of 0.53. Profusa has a one year low of $1.25 and a one year high of $3,000.00.

Profusa (NASDAQ:PFSA) last posted its quarterly earnings results on Wednesday, August 19th. The company reported ($151.80) EPS for the quarter.

Analyst Ratings Changes

Several brokerages have recently commented on PFSA. Weiss Ratings upgraded shares of Profusa from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, August 27th. Wall Street Zen raised shares of Profusa to a “sell” rating in a report on Saturday, August 22nd. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Insider Buying and Selling

In other Profusa news, major shareholder Financial Lp Hrt sold 10,602 shares of Profusa stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $3.56, for a total transaction of $37,743.12. Following the transaction, the insider owned 18,549 shares of the company’s stock, valued at $66,034.44. The trade was a 36.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have purchased 4,308 shares of company stock worth $16,594. 15.00% of the stock is currently owned by company insiders.

Profusa Company Profile

Profusa, Inc is a biotechnology company developing implantable biosensor technology designed to continuously monitor body chemistry. Its sensors are engineered to integrate with tissue and detect selected biological signals, with the goal of providing real-time health data through an external reader or connected digital device.

The company’s technology platform has been studied for applications including monitoring oxygen and other biomarkers that may assist with disease management, clinical research, and personalized healthcare.